A treatment designed to attack a common virus that hides in our bodies could ease the decline caused by multiple sclerosis (MS), according to new trial results. Excitingly, it may even reverse some of the symptoms. A phase 1 clinical trial by the California-based immunotherapy company Atara Biotherapeutics confirms latent Epstein-Barr (EBV) infections are viable targets for treating MS in at least some patients, reinforcing a curious link between the virus and a deadly illness that affects millions around the world. Out of the trial's 24 volunteers, 20 showed signs of either improvement or at least a halt in their...